Chemistry:Galactosamine
| |
-Galactosamine_Structural_Formulae_V.1.svg)
| |
| Names | |
|---|---|
| IUPAC name
2-Amino-2-deoxy-D-galactose
| |
| Other names
α-D-galactosamine
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C6H13NO5 | |
| Molar mass | 179.172 g·mol−1 |
| Melting point | 180 °C (356 °F; 453 K) (HCl salt) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Galactosamine is a hexosamine derived from galactose with the molecular formula C6H13NO5. This amino sugar is a constituent of some glycoprotein hormones such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
Precursors such as uridine diphosphate (UDP), UDP-N-acetyl-D-glucosamine, or glucosamine are used to synthesize galactosamine in the human body. A derivative of this compound is N-acetyl-D-galactosamine.[2]
Galactosamine is a hepatotoxic, or liver-damaging, agent that is sometimes used in animal models of liver failure.
Hepatotoxicity
Galactosamine is used to induce hepatitis in rodent liver for research purposes. The result of using galactosamine to induce hepatitis is a disease model in which there is necrosis and inflammation of the liver. This type of tissue damage triggered by galactosamine resembles drug-induced liver disease in humans.[3]
Mechanism of hepatotoxicity
The proposed mechanism behind galactosamine-induced hepatitis is depletion of the energy source of hepatocytes. In the Leloir pathway galactosamine is metabolized into galactosamine-1-phosphate (by galactokinase) and UDP-galactosamine (by UDP-galactose uridyltransferase). It is hypothesized that this leads to UDP-galactosamine accumulation within cells, and uridine triphosphate (UTP), UDP, and uridine monophosphate (UMP) decrease.[2] The depletion of high-energy molecules such as UTP leads to a disruption in hepatocyte metabolism. Additionally, other derivatives of uridine such as UDP-glucose are depleted and this interferes with glycogen synthesis in the cell.
Another recent hypothesis states that overexpression of pro-inflammatory cytokines (such as tumor necrosis factor (TNFα) and NFκB-dependent inducible nitric oxide synthase (iNOS) over expression play a role in galactosamine-induced damage to liver cells.[3]
See also
References
- ↑ Merck Index, 11th Edition, 4240.
- ↑ 2.0 2.1 Apte, U. (2014) (in en), Galactosamine, Elsevier, pp. 689–690, doi:10.1016/b978-0-12-386454-3.00315-8, ISBN 978-0-12-386455-0, https://linkinghub.elsevier.com/retrieve/pii/B9780123864543003158, retrieved 2022-12-08
- ↑ 3.0 3.1 Das, Joydeep; Ghosh, Jyotirmoy; Roy, Anandita; Sil, Parames C. (April 2012). "Mangiferin exerts hepatoprotective activity against D-galactosamine induced acute toxicity and oxidative/nitrosative stress via Nrf2–NFκB pathways" (in en). Toxicology and Applied Pharmacology 260 (1): 35–47. doi:10.1016/j.taap.2012.01.015. PMID 22310181. https://linkinghub.elsevier.com/retrieve/pii/S0041008X12000269.
External links
- Galactosamine at the US National Library of Medicine Medical Subject Headings (MeSH)
 |  |
